D3-GHR Polymorphism and Turner Syndrome

University Hospital Tuebingen

Overview

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome. Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

Study Type

OBSERVATIONAL

Conditions

Turner Syndrome Short Stature

Interventions

recombinant human growth hormoneDRUG

Eligibility

Sex: FEMALEMin age: 38 MonthsMax age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Turner syndrome defined by a structural aberration or lack of the X chromosome. * Growth velocity less than 2 cm/year at the time of final analysis (= final height). Exclusion Criteria: * Age \<3.5 or \>14 years at start of GH therapy, * GH peak serum levels \< 8 ng/ml in two independent tests, * Thelarche at start or during the first year of treatment, * Oxandrolone therapy for any time and a duration of GH therapy less than 2 years.

Locations (1)

University-Children's Hospital

Tübingen, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.